Use of Psilocybin for Improving Health-Related Outcomes and Mental State in Patients with Major Depressive Disorder: Protocol for a Living Systematic Review and Meta-Analysis (Preprint)
August 22, 2022 John M. Pederson, Kathryn Cowie, Averi Barrett et al.
BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of approximately 20-30 mg/70 kg. In the last decade, there has been renewed interest in using psilocybin for major depressive disorder (MDD). OBJECTIVE This individual patient data meta-analysis will investigate the efficacy and safety of psilocybin for...